K2M Group Holdings Inc. (NASDAQ:KTWO) dropped 2.8% during mid-day trading on Friday . The company traded as low as $16.82 and last traded at $16.86, with a volume of 157,509 shares trading hands. The stock had previously closed at $17.34.

KTWO has been the subject of a number of recent analyst reports. JMP Securities initiated coverage on shares of K2M Group Holdings in a report on Friday, April 8th. They set an “outperform” rating and a $25.00 price target for the company. Piper Jaffray Cos. restated a “buy” rating on shares of K2M Group Holdings in a report on Monday, April 25th. Northland Securities cut shares of K2M Group Holdings from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $21.00 price target on shares of K2M Group Holdings in a report on Tuesday, May 3rd. Finally, Zacks Investment Research cut shares of K2M Group Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.20.

The company’s market capitalization is $697.36 million. The company’s 50-day moving average price is $16.40 and its 200 day moving average price is $14.23.

K2M Group Holdings (NASDAQ:KTWO) last issued its quarterly earnings results on Wednesday, August 3rd. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.01. The business earned $59.20 million during the quarter, compared to analyst estimates of $57.47 million. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. On average, equities research analysts forecast that K2M Group Holdings Inc. will post ($1.10) EPS for the current fiscal year.

In other K2M Group Holdings news, CFO Gregory S. Cole sold 6,465 shares of K2M Group Holdings stock in a transaction on Saturday, May 21st. The shares were sold at an average price of $11.32, for a total value of $73,183.80. Following the sale, the chief financial officer now directly owns 33,233 shares in the company, valued at approximately $376,197.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several hedge funds and institutional investors have recently made changes to their positions in KTWO. Paradigm Capital Management Inc. NY increased its position in shares of K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock worth $3,350,000 after buying an additional 146,300 shares during the period. Principal Financial Group Inc. increased its position in shares of K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock worth $7,862,000 after buying an additional 5,127 shares during the period. New York State Common Retirement Fund increased its position in shares of K2M Group Holdings by 1.6% in the fourth quarter. New York State Common Retirement Fund now owns 141,690 shares of the medical device company’s stock worth $2,797,000 after buying an additional 2,170 shares during the period. Finally, Nationwide Fund Advisors increased its position in shares of K2M Group Holdings by 3.8% in the fourth quarter. Nationwide Fund Advisors now owns 98,318 shares of the medical device company’s stock worth $1,941,000 after buying an additional 3,597 shares during the period.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.